Skip to content
10-K

Annual Report

Voyager Therapeutics, Inc. VYGR

0001558370-25-002703

← back to feed
Filed
Mar 11, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 3, 2025 55.21M sh
Cash And Equivalents FY 2024 · Dec 31, 2023 $68.8M
Current Liabilities FY 2024 · Dec 31, 2023 $64.51M
Total Liabilities FY 2024 · Dec 31, 2023 $114.96M
Current Assets FY 2024 · Dec 31, 2023 $319.68M
Total Assets FY 2024 · Dec 31, 2023 $351.28M
Shares Diluted FY 2024 · Dec 31, 2022 38.36M sh
Capex FY 2024 · Dec 31, 2022 $2.49M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$12.51M
Eps Diluted FY 2024 · Dec 31, 2022 −$1.21
Eps Basic FY 2024 · Dec 31, 2022 −$1.21
Sga Expense FY 2024 · Dec 31, 2022 $30.98M
Rd Expense FY 2024 · Dec 31, 2022 $60.76M
Net Income FY 2024 · Dec 31, 2022 −$46.41M
Operating Income FY 2024 · Dec 31, 2022 −$50.84M
Revenue FY 2024 · Dec 31, 2022 $40.91M
Stockholders Equity FY 2024 · Dec 31, 2021 $95.06M